This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Chinese Academy of Sciences. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Innovative Contributions of Yufeng Xiao in the Field of Pharmacology
Introduction
Yufeng Xiao, an esteemed inventor based in Shanghai, China, has made significant strides in the field of pharmacology with a focus on receptor antagonists. His dedication to scientific research and innovation has led to the development of a notable patent that showcases his contributions to medicine.
Latest Patents
Yufeng Xiao holds a patent for a GPR84 receptor antagonist and its applications. This invention relates to a novel compound that acts as a GPR84 receptor antagonist, which is capable of competitively inhibiting receptor activation by an agonist associated with the GPR84 receptor. The patent outlines the structural formula of the antagonist and its potential to treat medical conditions such as multiple sclerosis, inflammatory bowel disease, and arthritis, which are linked to high expression or excitability of the GPR84 receptor.
Career Highlights
Yufeng Xiao is affiliated with the Chinese Academy of Sciences, where he conducts groundbreaking research. His commitment to advancing pharmaceutical sciences is reflected in his innovative approach to receptor antagonism. His work not only contributes to the scientific community but also has the potential to significantly improve treatment options for patients suffering from various chronic diseases.
Collaborations
Throughout his career, Yufeng Xiao has collaborated with other prominent researchers, including Fajun Nan and Xin Xie. These partnerships exemplify a collaborative approach to research, which enhances the development of innovative solutions in the field of medicine.
Conclusion
Yufeng Xiao’s contributions to the development of GPR84 receptor antagonists underscore the importance of innovative thinking in addressing complex medical challenges. His patent reflects a potential breakthrough in treating diseases associated with receptor dysfunction, promising new avenues for therapeutic intervention. As he continues his work at the Chinese Academy of Sciences, the scientific community looks forward to his future advancements in pharmacology.